Risks Related to Pharmaceutical Regulations and Revocation of Licenses and Approvals
First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2021: 2 of 14 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「If such licences and approvals are revoked due to violations of laws and regulations or other reasons, the Group may be required to recall products subject to regulation or discontinue their sale.」
The company continues to disclose the risks of pharmaceutical regulations, revocation of licences and approvals, product recalls and sales discontinuation. - FY2017RestatedAnnual report
「As of the present time, no grounds for revocation of the relevant licences and approvals have arisen. However, if such licences and approvals are revoked due to violations of laws and regulations or other reasons, the Group may be required to recall products subject to regulation or discontinue their sale.」
The company states that no grounds for revocation of licences and approvals have arisen as of the present time, while continuing to identify the risk of recalls and sales discontinuation due to violations of the Pharmaceuticals and Medical Devices Act and other laws and regulations. - FY2016First statedAnnual report
「If such licences and approvals are revoked due to violations of laws and regulations or other reasons, the Group may be required to recall products subject to regulation or discontinue their sale, and may be unable to continue the relevant business. This could disrupt the Group's operations and have a material impact on its business activities.」
The company describes the risks of violations of the Pharmaceuticals and Medical Devices Act and other laws and regulations, revocation of licences and approvals, product recalls and sales discontinuation.